Pablo Miguel
Barreiro Garcia
Hospital Universitario Reina Sofia
Córdoba, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario Reina Sofia (19)
2017
2016
-
Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013
Journal of Infection, Vol. 72, Núm. 5, pp. 587-596
-
MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression
PLoS ONE, Vol. 11, Núm. 5
2014
-
Association of low-density lipoprotein receptor genotypes with hepatitis C viral load
Genes and Immunity, Vol. 15, Núm. 1, pp. 16-24
-
Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions
PLoS ONE, Vol. 9, Núm. 12
-
Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy
Journal of Infection, Vol. 68, Núm. 4, pp. 372-377
-
Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes
International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6
2013
-
Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 32, Núm. 11, pp. 1427-1435
-
Pegylated interferon plus ribavirin is suboptimal inIL28B CC carriers without rapid response
Journal of Infection, Vol. 67, Núm. 1, pp. 59-64
-
Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection
AIDS, Vol. 27, Núm. 17, pp. 2715-2724
2012
-
Differences in virological response to peginterferon-a plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b
Journal of Acquired Immune Deficiency Syndromes, Vol. 60, Núm. 2, pp. 117-123
2011
-
Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype
HIV Medicine, Vol. 12, Núm. 8, pp. 487-493
-
Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV-hepatitis C virus-coinfected patients with prior nonresponse or relapse
AIDS, Vol. 25, Núm. 8, pp. 1131-1133
-
Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy
Journal of Infectious Diseases, Vol. 203, Núm. 11, pp. 1629-1636
2010
-
Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV
Clinical Infectious Diseases, Vol. 51, Núm. 10, pp. 1209-1216
2008
-
Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV co-infected patients
Journal of Hepatology, Vol. 49, Núm. 6, pp. 916-922
-
Efficacy of pegylated interferon plus ribavirin treatment in HIV/ hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone
Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 6, pp. 1365-1373
-
Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir
Antiviral Therapy, Vol. 13, Núm. 3, pp. 429-437
2004
-
Consensus conference on chronic viral hepatitis and HIV infection: Updated Spanish recommendations
Journal of Viral Hepatitis